Cel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report)’s share price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $1.67 and traded as high as $2.14. Cel-Sci shares last traded at $1.85, with a volume of 1,482,489 shares.
Cel-Sci Stock Up 11.4%
The company has a debt-to-equity ratio of 0.35, a current ratio of 1.48 and a quick ratio of 1.42. The firm has a 50 day simple moving average of $1.67 and a 200-day simple moving average of $2.29. The stock has a market capitalization of $32.34 million, a price-to-earnings ratio of -0.19 and a beta of 0.62.
Hedge Funds Weigh In On Cel-Sci
A hedge fund recently bought a new stake in Cel-Sci stock. WCG Wealth Advisors LLC bought a new position in shares of Cel-Sci Corporation (NYSEAMERICAN:CVM – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,260 shares of the company’s stock, valued at approximately $25,000. WCG Wealth Advisors LLC owned about 0.07% of Cel-Sci as of its most recent filing with the Securities & Exchange Commission. 12.08% of the stock is owned by institutional investors.
Cel-Sci Company Profile
CEL-SCI Corporation is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and other diseases. Its research includes treatments designed to stimulate or direct the body’s immune response. The company’s lead candidate, Multikine (leukocyte interleukin, injection), has been studied as a treatment before standard therapy for certain patients with head and neck cancer. Multikine is investigational and is not an approved treatment. CEL-SCI is also developing products using its Ligand Epitope Antigen Presentation System (LEAPS) technology, which is intended to target immune responses.
Further Reading
- Five stocks we like better than Cel-Sci
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Cel-Sci Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cel-Sci and related companies with MarketBeat.com's FREE daily email newsletter.
